The key selling point so far, based on phase 1 data, could be that it requires less frequent administrationit could be administered monthly, instead of the weekly Zepboundand may lead to longer maintenance of weight loss after stopping therapy. In addition, Andersen says Amgens offering has showed compelling speed of weight loss
Only if your vial concentration is 5 mg/mL
Child Neurol
Knowing your genetic context supports a more informed discussion with your provider about dose selection and tolerance expectations
Efficacy and safety of once-weekly dulaglutide in com-bination with sulphonylurea and/or biguanide compared with once-daily insulin glargine in Japanese patients with type 2 di-abetes: a randomized, open-label, phase III, non-inferiority study
Chris Renna, DO, founder of LifeSpan Medicine, to explore what healthspan really means and why most people start seeking answers only after symptoms have already taken hold